AEON Biopharma gets FDA Type 2b feedback on ABP-450 biosimilar path, files CMAP IND
AEON says FDA input and new analytical data support a combined approach to proving ABP-450 is biosimilar to BOTOX, with a pharmacodynamic study planned for Q1 2027 and cash into Q2 2027.
SEC filing